Use of eomesodermin to determine risk of allograft rejection

Patent metadata

Field	Value
Publication number	US-12372513-B2
Application number	US-202117245716-A
Country	US
Kind code	B2
Filing date	Apr 30, 2021
Priority date	Jan 23, 2015
Publication date	Jul 29, 2025
Grant date	Jul 29, 2025

Abstract

Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.

First claim

The invention claimed is:

1. A method of determining the risk of allograft rejection in a subject, wherein the subject is being treated with an immunosuppressive therapy but has not yet received an allograft, comprising:
isolating memory T cells from a peripheral blood mononuclear cell (PBMC) sample obtained from the subject;
exposing the isolated memory T cells to donor-derived cells ex vivo:
measuring expression of Eomesodermin (Eomes) in the memory T cells before and after exposure of the memory T cells to the donor-derived cells;
detecting an increase in expression of Eomes in the memory T cells after exposure to the donor-derived cells compared to expression of Eomes in the memory T cells before exposure to the donor-derived cells, thereby determining an increased risk for allograft rejection in the subject; and
treating the subject determined with the increased risk for allograft rejection with a modified immunosuppressive therapy, wherein the modified immunosuppressive therapy is selected from the group consisting of increasing the dose of the immunosuppressive therapy, increasing the frequency of the immunosuppressive therapy, administering an alternative immunosuppressive therapy and administering an additional immunosuppressive therapy.

2. The method of claim 1 , further comprising obtaining the PBMC sample from the subject.

3. The method of claim 1 , wherein the donor-derived cells are depleted of T-cells.

4. The method of claim 1 , wherein isolating memory T cells comprises isolating cells that express at least one memory T cell marker.

5. The method of claim 4 , wherein the at least one T cell marker is CD95, CD45RO, or both CD95 and CD45RO.

6. The method of claim 4 , wherein isolating memory T cells further comprises detecting the absence of expression of at least one naïve or effector T cell maker.

7. The method of claim 6 , wherein the at least one naïve or effector T cell marker is CD28, CD45RA, or both CD28 and CD45RA.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
• Univ Of Pittsburgh—Of The Commonwealth System

Inventors

• Ezzelarab Mohamed B
• Thomson Angus W

Classifications

• G01N2333/4703

  Regulators; Modulating activity · CPC title

• G01N33/5005 Primary

  involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025) · CPC title